Scholars Central

Conference abstractPublished 10 Sep 2012

Cholesterol masking of carbohydrate tumour antigens blocks tumour immune recognition and sheds new light on statin-based antineoplastic benefit

Authors: Clifford A. Lingwood, Anton Novak, Bo Ngan, Karen Chadwick, Neil Fleshner

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Glycosphingolipids (GSLs) are ceramide-carbohydrate conjugates important in differentiation, growth and intercellular interactions. GSL metabolism is abnormal in cancer, and ?tumour-associated GSL antigens?, often associated with embryonic development, can be cancer stem cell markers. GSLs and cholesterol accumulate in plasma membrane ?lipid rafts?- transmembrane signaling platforms which are increased in tumour cells. We have recently shown that the molecular interaction of GSLs with cholesterol can alter the conformation of the GSL carbohydrate, such that the sugar is changed from a membrane perpendicular to parallel format, which is largely unavailable for extracellular ligand binding (?invisible GSLs?). Since cholesterol metabolism is abnormal in cancer, we have investigated the efficacy of cholesterol depletion (via methylßcyclodextrin extraction) of primary human tumor biopsy sections to unmask previously undetectable tumour associated GSL antigens as an index of GSL masking in primary cancer tissues. For all cancers tested (ovarian, prostate, breast, Leydig, pheochromocytoma, neuroblastoma) cholesterol depletion induces immunostaining of previously undetectable tumour-associated GSLs. Such cholesterol mediated masking of GSL antigens may prevent effective tumour immunosurveillance to contribute to the extent of neoplastic disease. Since many clinical studies show antineoplastic benefit of statin therapy to lower serum cholesterol, we suggest that statin treatment may lower tumour cell membrane cholesterol levels to diminish tumour GSL masking and promote a more effective antitumour immune response. In a small sample of sera from prostate cancer patients who were, or were not, on statin therapy, immune-reactivity against prostate tumour GSLs was detected only in sera from statin treated patients.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Clifford A. Lingwood”
  • BylineArticles whose byline prints “Anton Novak”
  • BylineArticles whose byline prints “Bo Ngan”
  • BylineArticles whose byline prints “Karen Chadwick”
  • BylineArticles whose byline prints “Neil Fleshner”